Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Diagnostic Accuracy of Amyloid versus18F‐Fluorodeoxyglucose Positron Emission Tomography inAutopsy‐ConfirmedDementia
Orit H. Lesman‐Segev, Renaud La Joie, Leonardo Iaccarino, et al.
Annals of Neurology (2020) Vol. 89, Iss. 2, pp. 389-401
Open Access | Times Cited: 54

Showing 1-25 of 54 citing articles:

The Role of Amyloid PET in Imaging Neurodegenerative Disorders: A Review
Marianne Chapleau, Leonardo Iaccarino, David N. Soleimani‐Meigooni, et al.
Journal of Nuclear Medicine (2022) Vol. 63, Iss. Supplement 1, pp. 13S-19S
Open Access | Times Cited: 110
Automated detection of Alzheimer’s disease: a multi-modal approach with 3D MRI and amyloid PET
Giovanna Castellano, Andrea Esposito, Eufemia Lella, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 18
Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup
Gil D. Rabinovici, D. S. Knopman, Javier Arbizu, et al.
Alzheimer s & Dementia (2025)
Open Access | Times Cited: 12
Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup
Gil D. Rabinovici, D. S. Knopman, Javier Arbizu, et al.
Journal of Nuclear Medicine (2025), pp. jnumed.124.268756-jnumed.124.268756
Closed Access | Times Cited: 2
Donanemab: Appropriate use recommendations
G D Rabinovici, D. J. Selkoe, Suzanne E. Schindler, et al.
The Journal of Prevention of Alzheimer s Disease (2025), pp. 100150-100150
Open Access | Times Cited: 2
Recent update on the heterogeneity of the Alzheimer’s disease spectrum
K. A. Jellinger
Journal of Neural Transmission (2021) Vol. 129, Iss. 1, pp. 1-24
Closed Access | Times Cited: 87
18F-FDG PET Imaging in Neurodegenerative Dementing Disorders: Insights into Subtype Classification, Emerging Disease Categories, and Mixed Dementia with Copathologies
Satoshi Minoshima, Donna J. Cross, Tanyaluck Thientunyakit, et al.
Journal of Nuclear Medicine (2022) Vol. 63, Iss. Supplement 1, pp. 2S-12S
Open Access | Times Cited: 66
Brain [F-18]FDG PET for Clinical Dementia Workup: Differential Diagnosis of Alzheimer's Disease and Other Types of Dementing Disorders
Satoshi Minoshima, Karina Mosci, Donna J. Cross, et al.
Seminars in Nuclear Medicine (2021) Vol. 51, Iss. 3, pp. 230-240
Closed Access | Times Cited: 64
Amyloid‐β PET in Alzheimer's disease: A systematic review and Bayesian meta‐analysis
Dan Ruan, Long Sun
Brain and Behavior (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 40
The complex pathway between amyloid β and cognition: implications for therapy
William J. Jagust, Charlotte E. Teunissen, Charles DeCarli
The Lancet Neurology (2023) Vol. 22, Iss. 9, pp. 847-857
Open Access | Times Cited: 31
Scalable plasma and digital cognitive markers for diagnosis and prognosis of Alzheimer's disease and related dementias
Elena Tsoy, Renaud La Joie, Lawren VandeVrede, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 3, pp. 2089-2101
Open Access | Times Cited: 9
Neuroimaging in Frontotemporal Dementia: Heterogeneity and Relationships with Underlying Neuropathology
Bradley T. Peet, Salvatore Spina, Nidhi S. Mundada, et al.
Neurotherapeutics (2021) Vol. 18, Iss. 2, pp. 728-752
Open Access | Times Cited: 49
Declínio cognitivo subjetivo, comprometimento cognitivo leve e demência - diagnóstico sindrômico: recomendações do Departamento Científico de Neurologia Cognitiva e do Envelhecimento da Academia Brasileira de Neurologia
Jerusa Smid, Adalberto Studart‐Neto, Karolina Gouveia César‐Freitas, et al.
Dementia & Neuropsychologia (2022) Vol. 16, Iss. 3 suppl 1, pp. 1-24
Open Access | Times Cited: 31
Head-to-head comparison between plasma p-tau217 and flortaucipir-PET in amyloid-positive patients with cognitive impairment
Nidhi S. Mundada, Julio C. Rojas, Lawren VandeVrede, et al.
Alzheimer s Research & Therapy (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 22
Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions
Hye Kyu Choi, Meizi Chen, Li Ling Goldston, et al.
Nano Convergence (2024) Vol. 11, Iss. 1
Open Access | Times Cited: 6
A more precise diagnosis by means of amyloid PET contributes to delayed institutionalization, lower mortality, and reduced care costs in a tertiary memory clinic setting
Ingrid S. van Maurik, Hana M. Broulíková, Arenda Mank, et al.
Alzheimer s & Dementia (2022) Vol. 19, Iss. 5, pp. 2006-2013
Open Access | Times Cited: 26
Preclinical Alzheimer’s disease biomarkers accurately predict cognitive and neuropathological outcomes
Justin M. Long, Dean W. Coble, Chengjie Xiong, et al.
Brain (2022) Vol. 145, Iss. 12, pp. 4506-4518
Open Access | Times Cited: 25
Subjective cognitive decline, mild cognitive impairment, and dementia - syndromic approach: recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology
Jerusa Smid, Adalberto Studart‐Neto, Karolina Gouveia César‐Freitas, et al.
Dementia & Neuropsychologia (2022) Vol. 16, Iss. 3 suppl 1, pp. 1-24
Open Access | Times Cited: 24
Diagnostic biomarkers in Alzheimer’s disease
Emerlee Andersen, Bryce Casteigne, W. Chapman, et al.
Biomarkers in Neuropsychiatry (2021) Vol. 5, pp. 100041-100041
Open Access | Times Cited: 28
An efficient combination of quadruple biomarkers in binary classification using ensemble machine learning technique for early onset of Alzheimer disease
Rashmi Kumari, Akriti Nigam, Shashank Pushkar
Neural Computing and Applications (2022) Vol. 34, Iss. 14, pp. 11865-11884
Closed Access | Times Cited: 19
Considerations for biomarker strategies in clinical trials investigating tau-targeting therapeutics for Alzheimer’s disease
Lewis K. Penny, Richard Lofthouse, Mohammad Arastoo, et al.
Translational Neurodegeneration (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 4
Network anatomy in logopenic variant of primary progressive aphasia
Maria Luisa Mandelli, Diego L. Lorca‐Puls, Sladjana Lukic, et al.
Human Brain Mapping (2023) Vol. 44, Iss. 11, pp. 4390-4406
Open Access | Times Cited: 10
“Advances in biomarker discovery and diagnostics for alzheimer’s disease”
Vandana Bhatia, Abhimanyu Chandel, Yavnika Minhas, et al.
Neurological Sciences (2025)
Closed Access
The role of sleep in Alzheimer’s disease: a mini review
Jay Pathmanathan, M. Brandon Westover, Sudhir Sivakumaran, et al.
Frontiers in Neuroscience (2025) Vol. 19
Open Access
Correlation of early-phase β-amyloid positron-emission-tomography and neuropsychological testing in patients with Alzheimer’s disease
Friederike Völter, Sebastian Eckenweber, Maximilian Scheifele, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2025)
Open Access
Page 1 - Next Page

Scroll to top